Physician profile
Robert A Watson
NPI 1952396376
$5,696.41
in general payments reported to CMS, 2019-2025
42 companies · $948 in 2025
The $948 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $314 · 2021: $446 · 2022: $1,093 · 2023: $583 · 2024: $786 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,104.26 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Epic, Navitor |
| E.R. Squibb & Sons, L.L.C. | $565.33 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $489.38 | 2019-2025 | |
| Pfizer INC. | $364.09 | 2019-2025 | |
| Abiomed | $355.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.24 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Medtronic, INC. | $208.77 | 2021-2024 | Penditure |
| Boston Scientific Corporation | $197.89 | 2019-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $192.84 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.12 | 2019-2025 | Lifevest |
| Cvrx, INC. | $168.58 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $162.79 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $162.73 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.13 | 2019-2025 | Jardiance |
| Amgen INC. | $116.34 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $113.15 | 2019 | |
| Impulse Dynamics (USA) INC. | $99.48 | 2019-2023 | Optimizer |
| Atricure, INC. | $92.37 | 2020-2025 | Synergy Ablation System |
| Edwards Lifesciences Corporation | $66.40 | 2022-2023 | Hemosphere |
| Acutus Medical, INC. | $56.84 | 2022 | |
| Cardinal Health 200 LLC | $55.81 | 2019 | |
| Medtronic Vascular, INC. | $54.19 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $54.13 | 2023-2025 | Assure Wcd |
| Amarin Pharma, INC. | $43.81 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $39.09 | 2024-2025 | Giapreza |
| Teleflex LLC | $36.95 | 2024 | Manta |
| Sanofi-Aventis U.S. LLC | $35.73 | 2019-2023 | |
| Preventice Services, LLC | $30.13 | 2021 | |
| Livanova USA, INC. | $27.36 | 2022 | |
| Penumbra, INC. | $26.48 | 2022 | |
| Irhythm Technologies, INC. | $23.13 | 2023 | Zio Xt Patch |
| Endotronix, INC. | $22.53 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| Akcea Therapeutics, INC. | $20.28 | 2020 | |
| Glaxosmithkline, LLC. | $18.81 | 2019 | |
| Janssen Biotech, INC. | $16.76 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $16.22 | 2023 | Opsumit, Uptravi |
| Shockwave Medical, INC | $14.79 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medicomp INC | $14.14 | 2024 | Telepatch Cardiac Monitor |
| Terumo Medical Corporation | $13.62 | 2020 | |
| Biotronik INC. | $13.58 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.